View in EDS HTML Full Text PDF Full Text

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Saved in:
Bibliographic Details
Title: Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Authors: Patel, Shreyaskumar1 (AUTHOR) spatel@mdanderson.org, von Mehren, Margaret2 (AUTHOR), Reed, Damon R.3 (AUTHOR), Kaiser, Pamela4 (AUTHOR), Charlson, John5 (AUTHOR), Ryan, Christopher W.6 (AUTHOR), Rushing, Daniel7 (AUTHOR), Livingston, Michael8 (AUTHOR), Singh, Arun9 (AUTHOR), Seth, Rahul10 (AUTHOR), Forscher, Charles11 (AUTHOR), D'Amato, Gina12 (AUTHOR), Chawla, Sant P.13 (AUTHOR), McCarthy, Sharon14 (AUTHOR), Wang, George14 (AUTHOR), Parekh, Trilok14 (AUTHOR), Knoblauch, Roland14 (AUTHOR), Hensley, Martee L.15 (AUTHOR), Maki, Robert G.16 (AUTHOR), Demetri, George D.17 (AUTHOR)
Source: Cancer (0008543X). Aug2019, Vol. 125 Issue 15, p2610-2620. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:0008543X
DOI:10.1002/cncr.32117